Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Enzyme replacement therapy found to effectively treat patients with Fabry disease

25.10.2002


Raul Hernandez was no stranger to sports activity, and was active in Little League by the time he was 10 years old. But one day while running a short race at school, Raul experienced an intense burning sensation in his feet that turned his world upside down. From that day forward, he would experience severe pain in his feet any time he engaged in physical activity or, strangely, when the weather was hot or it rained. The situation worsened when the pain spread to his hands. His doctors, however, were unable to find anything wrong with him, telling his parents that the pain was all in his mind.



Seventeen years later, Raul was officially diagnosed with Fabry disease – a rare genetic disorder that causes severe pain in the hands and feet, eventually destroying vital organs in the body. Yet even after Raul was diagnosed, no therapy was available to treat the disease. It was not until two-and-a-half years ago that Raul learned that a clinical trial at Cedars-Sinai Medical Center was testing a new drug designed to replace the enzyme that he was missing. The next thing he knew, he was on a plane to Los Angeles from his hometown in Salinas, California to take part in the clinical trial. Since then, Raul commutes every two weeks to receive treatment. He says that he is once again exercising without pain and leads as normal life as anyone else.

An update of the clinical trial at Cedars-Sinai Medical Center and at 19 other centers throughout the country and Europe, was presented this month at the annual meeting of the American Society of Human Genetics in Baltimore, Maryland by William Wilcox, M.D., Ph.D., a medical geneticist at Cedars-Sinai. The findings show that patients receiving enzyme replacement therapy for a near-two-year period via infusion with a drug called r-haGAL (FabrazymeTM) continue to benefit from reduced pain and prevention of further organ damage.


"This study essentially confirms the long-term safety and effectiveness of enzyme replacement therapy for patients with Fabry," said Dr. Wilcox.

Named Fabry disease after the dermatologist who first noted the symptoms back in the 19th century, it was only recently discovered that the disease is an inherited disorder caused by the lack of a particular enzyme called a-galactosidase A or a-GAL. The enzyme is needed to break down a fatty substance in cells called globotriaosylceramide or GL-3. But when a-GAL is lacking, GL-3 builds up in blood vessel walls and does increasing damage to organs such as the heart, kidney and brain. By the time that the disease is diagnosed, the organs have often sustained damage, ultimately leading to an early death.

"Raul’s bout with the disease is similar to many other patients with Fabry, as even now, the disease is often undiagnosed until adulthood when organs have started being affected," said Dr. Wilcox. "Now we have a drug that replaces the deficient enzyme so that patients can live longer and better."

In the study, Raul was one of 58 patients selected at random to receive r-haGAL or a placebo by infusion every two weeks for a 20-week period. After completing 20 weeks of the study, all 58 patients have been receiving an infusion of r-haGAL every two-weeks for over 18 months. Patients’ response to the drug was monitored via kidney and heart function tests. Tissue biopsies were also performed to assess organ function and a specialized questionnaire was used to assess patient pain levels. The investigators found that pain was significantly improved overall, while pathology studies confirmed that GL-3, or the fatty substance in cells, was consistently reduced throughout the study period. Kidney function remained stable throughout treatment during the 18-month period indicating that the disease was not causing further damage.

Although the investigators found that the majority of patients began producing antibodies in response to the drug after a three-month period, this did not impact the continued effectiveness or safety of the drug.

"Interestingly, we found that enzyme replacement therapy continues to unplug blood vessels despite the presence of antibodies," commented Dr. Wilcox.

As one of the first patients to participate in the clinical trial, Raul says the treatment has changed his life. He can exercise and doesn’t have to worry about the weather.

Kelli Stauning | Cedars-Sinai Medical Center
Further information:
http://www.csmc.edu/

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>